- Conditions
- Lung Cancer
- Interventions
- Aerobic Training, Progressive Stretching, Resistance Training, Aerobic and Resistance Training
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 2,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease
- Interventions
- Red Light (PDT), Placebo
- Device
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Dapagliflozin, Metformin IR, Placebo matching with Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more
- Conditions
- Drug Dependence
- Interventions
- Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
- Drug · Behavioral
- Lead sponsor
- Friends Research Institute, Inc.
- Other
- Eligibility
- 15 Years to 21 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Obesity, Adolescent, Bariatric Surgery Candidate
- Interventions
- Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bacteremia
- Interventions
- Daptomycin, Vancomycin, Ceftaroline
- Drug
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- La Mesa, California • San Diego, California
- Conditions
- Pediatric Disorder
- Interventions
- Acetaminophen, Ibuprofen
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Aphasia, Language
- Interventions
- Real tDCS, Sham tDCS, Intensive Speech Therapy
- Device · Other
- Lead sponsor
- Austin Speech Labs
- Other
- Eligibility
- 20 Years to 85 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- Hybrid Coronary Revascularization (isolated LIMA-LAD), Hybrid Coronary Revascularization (PCI), Percutaneous Coronary Intervention
- Procedure · Device
- Lead sponsor
- Emilia Bagiella
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 39
- States / cities
- Long Beach, California • Los Angeles, California • Stanford, California + 31 more
- Conditions
- Parkinson Disease
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Arkansas Colleges of Health Education
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Fort Smith, Arkansas
- Conditions
- Liver Cirrhosis
- Interventions
- Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas
- Conditions
- Autism Spectrum Disorder
- Interventions
- Jasper, Parent Education
- Behavioral
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 18 Months to 59 Months
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Overweight and Obesity
- Interventions
- Full LIITA3H App, Partial LIITA3H App, LIITA3H Location only
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone implant, Aflibercept
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- iDSMES, Standard of Care
- Other
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 13 Years to 84 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Stroke
- Interventions
- REACH robotic training and multi-muscle Functional Electrical Stimulation (FES) group, Robot only group
- Combination Product
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Urothelial Carcinoma Bladder, Squamous Cell Carcinoma
- Interventions
- VET3-TGI, Atezolizumab
- Drug
- Lead sponsor
- KaliVir Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Orange, California • Miami, Florida + 4 more
- Conditions
- HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
- Interventions
- buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
- Drug
- Lead sponsor
- MetroHealth Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- cytarabine, daunorubicin hydrochloride, etoposide, valspodar, filgrastim, busulfan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, aldesleukin, clinical observation, pharmacological study
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- M200 (Volociximab), Liposomal Doxorubicin
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- Anaheim, California • Redondo Beach, California • Sunrise, Florida + 11 more
- Conditions
- Pertussis, Tetanus, Diphtheria
- Interventions
- ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,564 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Cypress, California + 15 more
- Conditions
- Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Germ Cell Tumors, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Osteosarcoma, Rhabdomyosarcoma
- Interventions
- Simvastatin, Cyclophosphamide, Topotecan, Myeloid growth factor
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
- Interventions
- DRP-104, atezolizumab
- Drug · Biological
- Lead sponsor
- Dracen Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- Paclitaxel, Ricolinostat, Bevacizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts